| Withdrawn | SMMART Adaptive Clinical Treatment (ACT) Trial NCT05238831 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Completed | Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcom NCT03317457 | AIO-Studien-gGmbH | Phase 2 |
| Completed | Combination of Cryosurgery and NK Immunotherapy for Recurrent Sarcoma NCT02849366 | Fuda Cancer Hospital, Guangzhou | Phase 1 / Phase 2 |
| Recruiting | Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Co NCT02701153 | Jonsson Comprehensive Cancer Center | N/A |
| Terminated | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants Wit NCT02609984 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Completed | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone NCT02357810 | Northwestern University | Phase 2 |
| Withdrawn | NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid NCT02059850 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma NCT02048722 | Northwestern University | Phase 2 |
| Completed | A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas NCT01782313 | Northwestern University | Phase 2 |
| Completed | Alisertib in Treating Patients With Advanced or Metastatic Sarcoma NCT01653028 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Biomarkers in Patients With Advanced Rhabdomyosarcoma NCT01668095 | Children's Oncology Group | — |
| Completed | Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery NCT01623869 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma NCT02507076 | Albert Einstein College of Medicine | N/A |
| Active Not Recruiting | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With NCT01552434 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma NCT01532687 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Ca NCT01477021 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma NCT01462630 | Fox Chase Cancer Center | Phase 2 |
| Completed | Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases NCT01586104 | Ann & Robert H Lurie Children's Hospital of Chicago | N/A |
| Completed | Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent NCT01281865 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients NCT01222715 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced NCT01206140 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced NCT01154452 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | 18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma NCT01169350 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue NCT01016015 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery NCT01553539 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma NCT00937495 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors NCT00831844 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metasta NCT00720174 | National Cancer Institute (NCI) | Phase 1 |
| Completed | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma NCT00659360 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagn NCT00638898 | City of Hope Medical Center | Phase 1 |
| Completed | Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) NCT00330421 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ixabepilone in Treating Young Patients With Refractory Solid Tumors NCT00331643 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma NCT00233948 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma NCT00245102 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma NCT00112463 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot NCT00098579 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Tha NCT00089544 | National Cancer Institute (NCI) | Phase 2 |
| Completed | CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor NCT00087074 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans NCT00084630 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191 | National Cancer Institute (NCI) | N/A |
| Completed | Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma NCT00064324 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma NCT00022542 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymph NCT00004241 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tiss NCT00019968 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Completed | Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Sof NCT00919269 | Children's Oncology Group | — |
| Withdrawn | Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcom NCT00017160 | Radiation Therapy Oncology Group | Phase 2 |